These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 16024640

  • 1. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
    Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD.
    Cancer Res; 2005 Jul 15; 65(14):6371-9. PubMed ID: 16024640
    [Abstract] [Full Text] [Related]

  • 2. Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy.
    Kuimova MK, Bhatti M, Deonarain M, Yahioglu G, Levitt JA, Stamati I, Suhling K, Phillips D.
    Photochem Photobiol Sci; 2007 Sep 15; 6(9):933-9. PubMed ID: 17721591
    [Abstract] [Full Text] [Related]

  • 3. Photoimmunotherapy of human ovarian carcinoma cells ex vivo.
    Goff BA, Bamberg M, Hasan T.
    Cancer Res; 1991 Sep 15; 51(18):4762-7. PubMed ID: 1716512
    [Abstract] [Full Text] [Related]

  • 4. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.
    Cancer Res; 2006 Jul 01; 66(13):6732-40. PubMed ID: 16818648
    [Abstract] [Full Text] [Related]

  • 5. Photochemical targeting of epidermal growth factor receptor: a mechanistic study.
    Savellano MD, Hasan T.
    Clin Cancer Res; 2005 Feb 15; 11(4):1658-68. PubMed ID: 15746071
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
    Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D.
    Cancer Res; 2006 Apr 01; 66(7):3764-72. PubMed ID: 16585203
    [Abstract] [Full Text] [Related]

  • 8. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC.
    Clin Cancer Res; 2000 Aug 01; 6(8):3334-41. PubMed ID: 10955821
    [Abstract] [Full Text] [Related]

  • 9. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.
    Cancer Res; 2009 Dec 01; 69(23):8987-95. PubMed ID: 19934334
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and in vitro testing of a pyropheophorbide-a-fullerene hexakis adduct immunoconjugate for photodynamic therapy.
    Rancan F, Helmreich M, Mölich A, Ermilov EA, Jux N, Röder B, Hirsch A, Böhm F.
    Bioconjug Chem; 2007 Dec 01; 18(4):1078-86. PubMed ID: 17550226
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1.
    Lattrich C, Juhasz-Boess I, Ortmann O, Treeck O.
    Oncol Rep; 2008 Mar 01; 19(3):811-7. PubMed ID: 18288420
    [Abstract] [Full Text] [Related]

  • 13. Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy.
    Vrouenraets MB, Visser GW, Stigter M, Oppelaar H, Snow GB, van Dongen GA.
    Cancer Res; 2001 Mar 01; 61(5):1970-5. PubMed ID: 11280754
    [Abstract] [Full Text] [Related]

  • 14. Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.
    Coyne CP, Ross MK, Bailey JG.
    J Drug Target; 2009 Jul 01; 17(6):474-89. PubMed ID: 19480561
    [Abstract] [Full Text] [Related]

  • 15. Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy.
    Vrouenraets MB, Visser GW, Stewart FA, Stigter M, Oppelaar H, Postmus PE, Snow GB, van Dongen GA.
    Cancer Res; 1999 Apr 01; 59(7):1505-13. PubMed ID: 10197621
    [Abstract] [Full Text] [Related]

  • 16. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY.
    Cancer Res; 2007 Mar 15; 67(6):2773-82. PubMed ID: 17363599
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate.
    Del Governatore M, Hamblin MR, Shea CR, Rizvi I, Molpus KG, Tanabe KK, Hasan T.
    Cancer Res; 2000 Aug 01; 60(15):4200-5. PubMed ID: 10945630
    [Abstract] [Full Text] [Related]

  • 19. Receptor-mediated DNA-targeted photoimmunotherapy.
    Karagiannis TC, Lobachevsky PN, Leung BK, White JM, Martin RF.
    Cancer Res; 2006 Nov 01; 66(21):10548-52. PubMed ID: 17079478
    [Abstract] [Full Text] [Related]

  • 20. Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates.
    Savellano MD, Hasan T.
    Photochem Photobiol; 2003 Apr 01; 77(4):431-9. PubMed ID: 12733655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.